Key result
Targeting RAAS shows promise for diabetic retinopathy by mitigating oxidative stress, inflammation, and angiogenesis.
Why the study?
Although RAAS inhibitors are often used to treat hypertension, the potential role and mechanism of RAAS in diabetic retinopathy require further study.
Answers are grounded in this paper and cite their sources.
RAAS inhibitors may serve as a promising therapeutic target for diabetic retinopathy by mitigating Ang II-induced oxidative stress, inflammation, and angiogenesis.
Diabetic retinopathy (DR) is a complication of diabetes with a complex pathophysiology and multiple factors involved. Recently, it has been found that the upregulation of the renin-angiotensin-aldosterone system (RAAS) leads to overexpression of angiotensin II (Ang II), which induces oxidative stress, inflammation, and angiogenesis in the retina. Therefore, RAAS may be a promising therapeutic target in DR. Notably, RAAS inhibitors are often used in the treatment of hypertension. Still, the potential role and mechanism of DR must be further studied. In this review, we discuss and summarize the pathology and potential therapeutic goals of RAAS in DR.
No takes yet. Share an insight, caveat, or question.
Li et al. (2024) conducted a review in Diabetic retinopathy. RAAS inhibitors was evaluated. Targeting the renin-angiotensin-aldosterone system (RAAS) may be a promising therapeutic strategy for diabetic retinopathy by mitigating oxidative stress, inflammation, and angiogenesis.
Synapse has enriched 10 related papers. Consider them for comparative context: